A new anticancer agent based on the conjugation of a photoactivatable Pt(IV) pro-drug to a cyclic RGD-containing peptide is described.
An integrin-targeted photoactivatable Pt(IV) complex as a selective anticancer pro-drug: synthesis and photoactivation studies † A new anticancer agent based on the conjugation of a photoactivatable Pt(IV) pro-drug to a cyclic RGD-containing peptide is described.
Upon visible light irradiation, phototoxicity was induced preferentially in SK-MEL-28 melanoma cancer cells overexpressing a V b 3 integrin compared to control DU-145 human prostate carcinoma cells.
The use of visible light has enormous potential in chemotherapy for controlling, at a desired time, the place and dose, and release of cytotoxic species from inert anticancer pro-drugs. For this reason, much effort has been dedicated to the development of photoactivatable metal-based anticancer complexes for improving drug efficacy and reducing toxic side-effects associated with platinum-based chemotherapeutic drugs currently used in clinics. 1 In addition, photoactivation offers the possibility for new mechanisms of action as well as the formation of novel adducts with the final biological target (not only DNA, but also RNA or proteins), which are important variables to overcome inherent or acquired resistance to cisplatin. Among photoactivated metallodrugs, Pt(IV) diazidodihydroxido complexes are particularly promising since they are inert and nontoxic in the dark, but become highly active against a range of cancer cell lines upon irradiation with visible light, including cisplatin-resistant cells (A2780cis As recently found by us for conjugates between a Pt(IV) derivative of picoplatin and RGD-containing peptides, 9d we hypothesize that the peptide vector will confer complex 1 with selectivity for cancer cells overexpressing pro-angiogenic integrins such as a V b 3 and a V b 5 . The novelty of this approach resides in the use of a photoactivatable Pt(IV) pro-drug since irradiation with visible light directly within the tumour will trigger the release of cytotoxic Pt(II) species from the internalized conjugate (3 in Fig. 1 ), thus providing a Pt(IV)-based anticancer agent with dual control over selectivity. First, one of the axial hydroxyl groups of complex 1 was esterified with succinic anhydride to generate trans,trans,trans-[Pt(N 3 ) 2 (OH)(succ)(py) 2 ] (2) (Fig. 1) , 10 which contains a carboxylic acid function suitable for attaching the peptide moiety. As shown in Fig Next, the efficiency of the photoactivation of Pt-c(RGDfK) conjugate (3) in the presence of 5 0 -GMP (2 mol equiv.) was investigated by HPLC-MS. As shown in Fig. S4 indicating that the attached peptide does not alter the photochemical properties or the type of photoadducts with a model nucleobase. Furthermore, the release of the intact succinate-c(RGDfK) moiety (5 in Fig. 2 ) implies that the carrier ligand neither competes with 5 0 -GMP for binding to the photoreleased Pt(II) species, nor does it form any secondary reactions, being a simple targeting vector of the Pt(IV) pro-drug.
Having established the photoactivation properties of the Pt-c(RGDfK) conjugate, our next objective was to investigate its toxicity towards different cancer cell lines in the presence of visible light to assess the capacity of the peptide vector to deliver the photoactivatable Pt(IV) pro-drug into cancer cells overexpressing integrin receptors. On the basis of flow cytometry studies (Fig. 4) , we selected SK-MEL-28 human malignant melanoma cell line as a model to evaluate the phototoxicity of 3 since it expresses high levels of a V b 3 integrin compared with a V b 5 integrin (mean cell fluorescence intensity of 217.4 and 23.3 for a V b 3 and a V b 5 integrins, respectively). 9d As negative control, the DU-145 human prostate carcinoma cell line was selected since the expression of a V b 3 integrin was considerably lower, whereas that of a V b 5 integrin was similar (mean cell fluorescence intensity of 16.6 and 31.8 for a V b 3 and a V b 5 integrins, respectively). As expected, the internalization of the fluorescein-labelled RGD-containing peptide, Fluo-c(RGDfK) (7), 9d was slightly higher in the a V b 3 integrin overexpressing SK-MEL-28 cells than in DU-145 (by 1.6-fold when incubated at 10 mM; see Fig. S5 , ESI †), which points to the active participation of this integrin receptor in the uptake of the peptide. The photocytotoxicity of the Pt-c(RGDfK) conjugate (3) and of the parent Pt complexes (1 and 2) was determined upon irradiation with visible light (l irr = 420 nm, 5 J cm À2 ) in both cell lines. The photoactivated dose-dependent inhibition of cell viability for compounds 1-3 towards SK-MEL-28 and DU-145 cells and their phototoxic indices are summarised in Table 1 and the cytotoxicity plots are shown in Fig. S6 (ESI †) . First, it is worth noting that the IC 50 value for complex 1 in SK-MEL-28 was similar to those previously found in other cancer cell lines (IC 50 = 6.8 mM in HaCaT, 8.3 mM in A2780 or 8.4 mM in OE19, under blue light irradiation), 2b although the cytotoxicity in DU-145 cells was about 4-fold lower than in the melanoma cancer cell line. Hence, these results confirm the high antitumour efficiency of the Pt(IV) pro-drug against cancer cells of different origin when photoactivated with visible light. Second, the cytotoxic effect of 1 was slightly reduced in SK-MEL-28 (about 1.5-fold) upon derivatization with a succinate group (2). This tendency was not reproduced in DU-145, since the cytotoxic effect was increased upon succinylation (IC 50 = 20 mM for 2 vs. IC 50 = 43 mM for 1).
As shown in Table 1 , the phototoxicity of conjugate 3 in SK-MEL-28 (IC 50 = 19.5 mM) was similar to that of the parent succinylated complex 2 (IC 50 = 15.5 mM), whereas the differences in the irradiated mean IC 50 values were higher in DU-145 cells (IC 50 = 20 mM for 2 and 54 mM for 3). This result is in good agreement with the levels of expression of the a V b 3 integrin and with the cellular uptake experiments with the fluorescein-labelled peptide, and is consistent with the participation of the receptor in the biological activity of the conjugate. Hence, conjugation to the RGD-containing peptide vector seems to confer selectivity to complex 2 since the anticancer activity is higher in the melanoma cancer cell line that overexpresses a V b 3 integrin receptor whereas a lower phototoxicity was found in the human prostate cancer cell line. This difference was increased when conjugate 3 was irradiated with UVA (l irr = 365 nm, 5 J cm À2 ) in both cell lines.
Interestingly, DU-145 cells treated with aminolevulinic acid (ALA) using the same blue light source were twice more susceptible than SK-MEL-28 cells (irradiated mean IC 50 values = 0.12 mM and 0.23 mM, respectively). Thus, the melanoma cancer cells were more resistant to the porphyrin-based therapy, but more sensitive to the Pt-based therapy compared to the prostate cancer cells.
Since the cellular uptake of the Pt-peptide conjugate depends both on the level of expression of the pro-angiogenic integrins and on the binding affinity of the RGD-containing peptide towards these receptors, the determination of the intracellular accumulation is of high importance to assess the effect of the peptide conjugation on the biological activity of the Pt(IV) pro-drug as well as to investigate the contribution of each integrin subtype. For this purpose, in addition to SK-MEL-28 and DU-145 cells, we selected the MBA-MD-468 breast adenocarcinoma cell line as positive control for a V b 5 integrin. As shown in Fig. 4 , the expression of a V b 5 integrin was considerably higher than that of a V b 3 integrin (mean cell fluorescence intensity of 3.8 and 42.4 for a V b 3 and a V b 5 integrins, respectively). Then, the three cancer cell lines were exposed to 10 mM solutions of 1-3 in the dark for 1 h, and the intracellular level of platinum was quantified by inductivelycoupled plasma mass spectrometry (ICP-MS).
As shown in Fig. 5 , the accumulation of platinum after exposure of the three cell lines to Pt-c(RGDfK) conjugate (3 To our surprise, the intracellular accumulation of 3 in MBA-MD-468 was also higher than in DU-145 cells (about 3.6-fold) despite the very low expression of a V b 3 integrin in the breast carcinoma cell line. These results and the fact that accumulation of 3 in MBA-MD-468 was about 1. Table 1 ): a lower IC 50 value upon visible light irradiation and a higher phototoxic index was found in the melanoma cancer cells that accumulated a higher amount of the compound compared with prostate carcinoma cells. Notably, the accumulation of 1 and 2 in SK-MEL-28 and MBA-MD-468 cells was also higher than in DU-145, thereby revealing a preference for the melanoma and breast cancer cells. It is also interesting that despite the higher accumulation of conjugate 3 compared with the parent complexes, the phototoxicity was slightly reduced, particularly when compared with 1 in SK-MEL-28. This might be attributable to differences in the quantum yield of the compounds and to the accumulation of the conjugate in intracellular vesicles that might interfere with the interaction of the released Pt(II) species with the target.
In conclusion, our results demonstrate the potential of conjugating photoactivatable metal complexes, such as Pt(IV) pro-drugs, to peptides with the aim of generating receptortargeted metal-based anticancer drugs with reduced toxic side effects based on dual control over selectivity. The fact that the Pt-c(RGDfK) conjugate can also be internalized by a V b 5 integrin opens up the door to delivering such promising anticancer metallodrugs to tumours overexpressing a V b 5 integrin 13 or to tumours coexpressing both a V b 3 and a V b 5 integrins. 7b,14 Such a multiintegrin targeting approach would provide new metal-based anticancer strategies and so benefit a wider range of patients by increasing the number of tumours which can be targeted. 
